Eosinophilic Esophagitis Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Eosinophilic Esophagitis Overview

Eosinophilic esophagitis (EoE) is a chronic disorder of the digestive system in which large numbers of a particular type of white blood cell called eosinophils are present in the esophagus. The esophagus is the tube that carries food from the mouth to the stomach.

“Eosinophilic Esophagitis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Eosinophilic Esophagitis Market.

The Eosinophilic Esophagitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Eosinophilic Esophagitis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Eosinophilic Esophagitis treatment therapies with a considerable amount of success over the years. Eosinophilic Esophagitis Key players such as – Serpin Pharma, Landos Biopharma, Aqilion, Calypso Biotech, Pfizer, EsoCap, Revolo Biotherapeutics, Ellodi Pharmaceuticals, AstraZeneca, and others, are developing therapies for the Eosinophilic Esophagitis treatment 

• Eosinophilic Esophagitis Emerging therapies such as – SP 16, Omilancor, AQ280, CALY-002, Etrasimod, Mometasone, IRL201104, APT-1011, Benralizumab, and others are expected to have a significant impact on the Eosinophilic Esophagitis market in the coming years.   
• In September 2021, Ellodi Pharmaceuticals initiated an adolescent sub-study within FLUTE-2: a randomized, double-blind, placebo-controlled study of APT-1011 (Fluticasone Propionate Oral Dispersible Tablet Formulation), with an open-label extension, in adolescent subjects with Eosinophilic Esophagitis
• In February 2021, Ellodi Pharmaceuticals announced that APT-1011 (fluticasone propionate oral disintegrating tablet) received Fast Track designation by the US Food and Drug Administration (FDA) for the treatment of Eosinophilic Esophagitis (EoE)

Route of Administration

Eosinophilic Esophagitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intravenous

Molecule Type

Products have been categorized under various Molecule types, such as

• Peptides
• Protein
• Small molecule
• Cell therapy 

Eosinophilic Esophagitis Pipeline Therapeutics Assessment

• Eosinophilic Esophagitis Assessment by Product Type
• Eosinophilic Esophagitis By Stage and Product Type
• Eosinophilic Esophagitis Assessment by Route of Administration
• Eosinophilic Esophagitis By Stage and Route of Administration
• Eosinophilic Esophagitis Assessment by Molecule Type
• Eosinophilic Esophagitis by Stage and Molecule Type

DelveInsight’s Eosinophilic Esophagitis Report covers around 20+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Eosinophilic Esophagitis Therapeutics Market include:

Key companies developing therapies for Eosinophilic Esophagitis are – Takeda Pharmaceuticals, Ellodi Pharmaceuticals, Bristol Myers Squibb, AstraZeneca, GlaxoSmithKline, Regeneron Pharmaceuticals (Sanofi), Allakos Inc, Arena Pharmaceuticals, Revolo Biotherapeutics, DBV Technologies, Landos Biopharma, and others.

Emerging Eosinophilic Esophagitis Drugs Under Different Phases of Clinical Development Include:

• SP 16: Serpin Pharma
• Omilancor: Landos Biopharma
• AQ280: Aqilion
• CALY-002: Calypso Biotech
• Etrasimod: Pfizer
• Mometasone: EsoCap
• IRL201104: Revolo Biotherapeutics
• APT-1011: Ellodi Pharmaceuticals
• Benralizumab: AstraZeneca

Get a Free Sample PDF Report to know more about Eosinophilic Esophagitis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight

Eosinophilic Esophagitis Pipeline Analysis:

The Eosinophilic Esophagitis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Eosinophilic Esophagitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Eosinophilic Esophagitis Treatment.
• Eosinophilic Esophagitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Eosinophilic Esophagitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Eosinophilic Esophagitis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Eosinophilic Esophagitis product details are provided in the report. Download the Eosinophilic Esophagitis pipeline report to learn more about the emerging Eosinophilic Esophagitis therapies

Eosinophilic Esophagitis Pipeline Market Drivers

• Increasing awareness programs for Eosinophil-associated disorders
• Introduction of high-priced biologics

Eosinophilic Esophagitis Pipeline Market Barriers

• Increasing awareness programs for Eosinophil-associated disorders
• Introduction of high-priced biologics.

Scope of Eosinophilic Esophagitis Pipeline Drug Insight    

• Coverage: Global
• Key Eosinophilic Esophagitis Companies: Serpin Pharma, Landos Biopharma, Aqilion, Calypso Biotech, Pfizer, EsoCap, Revolo Biotherapeutics, Ellodi Pharmaceuticals, AstraZeneca, and others
• Key Eosinophilic Esophagitis Therapies: SP 16, Omilancor, AQ280, CALY-002, Etrasimod, Mometasone, IRL201104, APT-1011, Benralizumab, and others
• Eosinophilic Esophagitis Therapeutic Assessment: Eosinophilic Esophagitis current marketed and Eosinophilic Esophagitis emerging therapies
• Eosinophilic Esophagitis Market Dynamics: Eosinophilic Esophagitis market drivers and Eosinophilic Esophagitis market barriers 

Request for Sample PDF Report for Eosinophilic Esophagitis Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Eosinophilic Esophagitis drugs and therapies 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services